FT Markets

Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo ...

Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability – – STRATUS-HCM includes two ...
Yahoo Finance

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026

SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver ...
Yahoo Finance

Hannah Cranston Media (HCM) Named to Inc.'s 2026 Best Workplaces List

NEW YORK, June 2, 2026 /PRNewswire/ -- Hannah Cranston Media (HCM) is proud to announce it has been named to Inc.'s 2026 Best Workplaces list. The list, which can be found at Inc.com, honors American ...
TipRanks

Braveheart Bio Reports Positive 52-Week HCM Study Data

On November 6, 2026, Braveheart Bio and Hengrui Pharma presented 52-week open-label extension data from a Phase 2 study of HRS/BHB-1893 in obstructive HCM at the American Heart As ...